NUTRACEUTICALS VERSUS PHARMACEUTICALS IN THE MANAGEMENT OF HYPERTENSION: MECHANISMS, THERAPEUTIC ROLES, EVIDENCE, SAFETY AND FUTURE PERSPECTIVES

Abstract

Hypertension is a major chronic cardiovascular disorder characterized by persistently elevated arterial blood pressure and is associated with increased risks of cardiovascular, cerebrovascular and renal complications. Its pathophysiology involves multiple interacting mechanisms, including abnormal renal sodium handling, activation of the renin–angiotensin–aldosterone system (RAAS), sympathetic overactivity, endothelial dysfunction, altered vascular tone, oxidative stress and inflammatory processes. Conventional pharmaceutical therapy remains the principal evidence-based strategy when pharmacological treatment is indicated. Antihypertensive medicines provide defined pharmacological targets, standardized doses, predictable pharmacodynamic effects and established clinical indications. Major therapeutic classes include thiazide and thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium-channel blockers, beta-blockers, mineralocorticoid-receptor antagonists and selected second-line agents. In parallel, increasing interest has developed in nutraceuticals and food-derived bioactive compounds as complementary approaches for cardiovascular health and blood-pressure management. Nutraceuticals relevant to hypertension include potassium, magnesium, omega-3 fatty acids, garlic and aged garlic preparations, milk-derived bioactive peptides, polyphenols, flavonoids, cocoa, tea, lycopene, coenzyme Q10, L-arginine, taurine, vitamins and selected standardized plant extracts. These substances may influence several pathways associated with blood-pressure regulation, including endothelial nitric-oxide availability, oxidative stress, vascular relaxation, inflammation, mineral balance and, in some cases, RAAS activity. However, nutraceuticals and pharmaceuticals should not be considered therapeutically equivalent. The major distinction is not simply “natural versus synthetic,” but rather the degree of standardization, dose definition, pharmacokinetic characterization, quality control, evidence strength, reproducibility and magnitude of clinical effect. Nutraceutical evidence remains heterogeneous because studies frequently differ in preparation, dose, formulation, duration and participant characteristics. Moreover, food-derived origin does not guarantee safety, particularly in patients receiving antihypertensive medicines. This review critically examines the mechanistic and therapeutic differences between nutraceutical and pharmaceutical approaches to hypertension, with particular emphasis on pharmacodynamics, ADME characteristics, standardization, safety, evidence quality, clinical positioning and the role of pharmacists. The available evidence supports an integrated model in which healthy dietary practices and selected evidence-informed nutraceutical interventions complement, rather than replace, appropriate antihypertensive pharmacotherapy.